The volume and complexity of drug safety data continue to increase across the pharmaceutical industry. Safety teams are now expected to evaluate information from spontaneous adverse event reports, clinical trials, scientific literature, patient support programmes, electronic health records, social media, and other real-world data sources. At the same time, regulatory expectations for timely safety surveillance remain high.
As organisations manage growing workloads, many are exploring how artificial intelligence (AI) can support pharmacovigilance activities. For many drug safety teams, the practical question is where AI can reduce manual burden, improve consistency and support faster review within established pharmacovigilance processes.
However, AI is not a replacement for scientific or clinical expertise. As regulators including the FDA and European Medicines Agency (EMA) develop expectations around the role of AI in healthcare, organisations are focusing on how these technologies can be implemented responsibly while maintaining patient safety and regulatory compliance.
This article explores how AI is changing drug safety, where it is currently being used in pharmacovigilance, and the considerations organisations should address before implementation.
What is AI in Pharmacovigilance?
AI in pharmacovigilance refers to the use of AI technologies that assist with the detection, extraction, classification, prioritisation, and monitoring of drug safety information. In practical terms, artificial intelligence in pharmacovigilance is usually best understood in terms of introducing efficiency in high-volume traditionally fully manual tasks, and as decision support for, data-heavy safety activities.
Modern pharmacovigilance AI solutions typically incorporate:
- Machine learning algorithms that identify patterns within large datasets
- Natural language processing (NLP) tools that interpret unstructured text
- Large language models (LLMs) that support information extraction and summarisation
- Predictive analytics that help identify potential safety risks
Rather than replacing human decision-making, AI functions primarily as a decision-support capability. Many current applications focus on automating repetitive activities, improving data quality, and helping safety professionals manage increasing volumes of information.
This distinction is important because pharmacovigilance requires scientific judgement, medical interpretation, and regulatory accountability. While AI can support these activities, responsibility for safety decisions remains with qualified professionals.
Why Drug Safety Teams are Turning to AI
The increasing adoption of artificial intelligence in pharmacovigilance is being driven by operational and scientific challenges across the drug development lifecycle.
Increasing Case Volumes
Global reporting requirements and growing patient populations have resulted in larger numbers of Individual Case Safety Reports (ICSRs). Processing these reports manually can place considerable pressure on pharmacovigilance teams.
Growing Volumes of Unstructured Data
Much of the information used in drug safety activities exists in unstructured formats, including medical narratives, scientific publications, physician notes, and patient communications. Extracting meaningful information from these sources is often time-consuming when performed manually.
Expanding Literature Monitoring Requirements
Scientific literature remains a critical source of safety information. However, monitoring thousands of publications across multiple therapeutic areas creates a significant resource burden for organisations.
Increasing Use of Real-World Data
Healthcare databases, registries, and electronic health records are generating large quantities of real-world evidence. While these sources can provide valuable safety insights, analysing them effectively often requires advanced analytical approaches.
How AI is Changing Pharmacovigilance Workflows
AI is increasingly being integrated into operational pharmacovigilance processes.
Case Intake and Data Extraction
NLP technologies can review incoming reports and extract relevant information such as patient demographics, suspect products, adverse events, concomitant medications, and outcomes. Data can be automatically populated in the relevant safety database fields.
This can improve workflow efficiency, reduce manual transcription activities and improve consistency in data capture.
Triage and Prioritisation
Not all safety reports require the same level of urgency. AI tools can help categorise and prioritise cases based on predefined criteria, enabling safety professionals to focus attention where it is most needed.
Duplicate Detection
Duplicate case identification remains an important challenge in pharmacovigilance. Machine learning algorithms can compare multiple case attributes simultaneously and identify reports that may represent the same event.
This helps reduce redundant processing and improves the accuracy of safety databases.
Coding Support
AI applications can assist with coding adverse events using Medical Dictionary for Regulatory Activities (MedDRA) terminology and assigning medicinal product classifications through WHODrug dictionaries.
Although coding decisions still require review, AI can help improve consistency and reduce processing times.
Literature Monitoring
Several AI-enabled systems are now being used to support literature surveillance activities.
Potential benefits include:
- Faster screening of publications.
- Identification of articles likely to contain safety information.
- Reduced manual review burden.
- Improved consistency across screening activities.
These capabilities are particularly valuable as publication volumes continue to increase across therapeutic areas.
Reporting and Quality Review Support
AI may also support reporting-related activities, such as drafting structured case narratives, summarising source documents, checking internal consistency and flagging missing information before medical or quality review. These outputs should remain reviewable and traceable, particularly where they feed into regulated reporting processes.
How AI is Changing Signal Detection and Safety Surveillance
Signal detection is one of the most frequently discussed applications of AI in pharmacovigilance.
Traditionally, signal detection has relied on statistical methods, clinical review, and expert evaluation of safety databases. AI introduces additional analytical capabilities by enabling organisations to evaluate larger and more diverse datasets simultaneously.
AI systems can analyse:
- Spontaneous adverse event reports
- Clinical trial safety data
- Electronic health records
- Scientific literature
- Product labels
- Real-world evidence datasets
By identifying patterns, associations, and emerging trends, AI may help support earlier identification of potential safety concerns.
Importantly, AI does not replace established signal management processes. Potential signals identified through AI systems still require clinical assessment, medical review, and regulatory evaluation before conclusions can be drawn.
How AI is Changing Risk Prediction in Drug Safety
Beyond operational efficiency, researchers are exploring how AI may support predictive approaches to drug safety.
Adverse Drug Reaction Prediction
Machine learning models are being investigated for their ability to identify patterns associated with adverse drug reactions before signals become apparent through conventional reporting pathways.
Drug–Drug Interaction Detection
AI systems can analyse large datasets containing prescribing information, patient outcomes, and clinical observations to identify interaction patterns that warrant further investigation.
Seriousness Prediction
Some models aim to predict the likelihood that a report may involve a serious outcome. This may assist with case prioritisation and resource allocation.
Benefit–Risk Assessment Support
AI technologies can help aggregate information from multiple data sources, providing additional analytical support for benefit–risk evaluations.
While these applications show promise, many remain under active development and require further validation before widespread adoption in regulatory decision-making environments.
Why Human Judgement Still Matters in AI-Enabled Drug Safety
Despite advances in artificial intelligence, human expertise remains central to pharmacovigilance.
Drug safety assessments frequently face incomplete information, conflicting evidence, and complex clinical considerations. Activities such as causality assessment require contextual interpretation that extends beyond pattern recognition.
Human oversight remains essential for:
- Medical review of cases
- Signal validation
- Benefit–risk assessment
- Regulatory communication
- Final safety decision-making
Regulatory agencies consistently emphasise the importance of maintaining appropriate human oversight when AI technologies are used within regulated processes.
For this reason, successful AI implementation should be viewed as a partnership between technology and expert judgement rather than a replacement strategy.
What Controls are Needed When Implementing AI in PV?
The adoption of AI in pharmacovigilance requires robust governance and lifecycle management.
Key controls typically include:
Validation
Organisations should demonstrate that AI systems perform consistently and appropriately within their intended use.
Documentation
Comprehensive documentation supports transparency and regulatory inspection readiness.
Audit Trails
Maintaining traceability helps organisations understand how outputs were generated and reviewed.
Version Control
Models should be managed through formal change-control processes to ensure consistency and accountability.
Performance Monitoring
Ongoing monitoring is necessary to identify performance degradation, bias, or model drift over time.
Workflow Design
AI tools should be embedded into defined pharmacovigilance workflows, with clear hand-off points, review steps and escalation routes. This helps prevent outputs being used outside their intended purpose.
Staff Training
Users should understand both the capabilities and limitations of AI systems to ensure appropriate use. Training should also cover how to challenge outputs, document review decisions and recognise when manual escalation is needed.
Controlled Implementation
Implementation should include user acceptance testing, process updates and clear communication on how roles and responsibilities may change. Without this, technically capable systems can still fail to deliver consistent operational value.
Governance Frameworks
Clear governance structures help define responsibilities, oversight mechanisms, and escalation pathways when issues arise.
What are the Risks and Limitations of AI in PV?
While AI offers practical opportunities, several limitations must be considered.
Data Quality
AI outputs are heavily influenced by the quality of underlying data. Incomplete, inaccurate, or inconsistent information can affect performance.
Bias
Training datasets may contain biases that influence model outputs and decision-support recommendations.
Rare Safety Events
Rare adverse events remain difficult for many AI systems to identify reliably because of limited training examples.
False Positives and False Negatives
AI systems may incorrectly flag irrelevant cases or miss information that requires review. Both outcomes matter in pharmacovigilance because they can affect workload, prioritisation and confidence in the process.
Explainability
Some AI models operate as ‘black boxes’, making it challenging to understand how outputs were generated.
Privacy and Data Protection
Organisations must ensure compliance with applicable privacy requirements, including GDPR and other regional regulations.
Model Drift
Changes in data patterns over time may reduce model performance if systems are not monitored and updated appropriately.
System Integration
Integrating AI technologies into existing pharmacovigilance infrastructure can require significant investment and organisational change. Legacy safety systems, data standards, vendor platforms and validation requirements can all affect how quickly a tool can move from pilot use to routine operation.
Cost and Scalability
AI implementation may require investment in technology, validation, governance, training and ongoing monitoring. Organisations should assess whether a use case is scalable and sustainable before embedding it into business-critical PV processes.
What is the Regulatory Position of AI in PV?
Regulatory agencies recognise the growing importance of AI in healthcare and life sciences, including pharmacovigilance.
Current discussions from the FDA, EMA, and Council for International Organizations of Medical Sciences (CIOMS) generally focus on several common themes:
- Transparency
- Validation
- Human oversight
- Data quality
- Bias mitigation
- Risk-based governance
- Documentation and traceability
The FDA has issued draft guidance on the use of AI to support regulatory decision-making for drug and biological products, with an emphasis on credibility, risk-based assessment and context of use. In pharmacovigilance specifically, CDER’s Emerging Drug Safety Technology Program provides a route for discussion on AI and other emerging technologies used in drug safety activities.
In Europe, the EMA’s reflection paper on AI in the medicinal product lifecycle points to similar themes, including human oversight, risk management, data quality and the need for lifecycle controls when AI is used in development, authorisation or post-authorisation settings.
This regulatory direction does not prevent AI adoption, but it does require organisations to demonstrate that systems are appropriately validated, fit for purpose, and supported by adequate oversight mechanisms.
As AI technologies continue to evolve, regulatory expectations are also likely to develop. Organisations implementing AI should therefore maintain ongoing engagement with emerging guidance and industry best practices.
Conclusion
Artificial intelligence is increasingly influencing how pharmacovigilance activities are performed. From case intake and literature monitoring to signal detection and risk assessment, AI technologies can help organisations manage growing volumes of safety information while supporting operational efficiency.
However, successful implementation depends on more than technology alone. Data quality, governance, validation, transparency, and expert oversight remain essential components of responsible AI adoption.
As regulatory expectations continue to evolve, organisations should focus on implementing AI-enabled pharmacovigilance processes that strengthen existing drug safety frameworks while maintaining scientific rigour, regulatory compliance, and patient safety.
About QVigilance
We are a specialised pharmacovigilance service provider, offering comprehensive pharmacovigilance services to sponsors of clinical trials and manufacturers of authorised medicinal products. QVigilance is adept in supporting customers establishing a compliant pharmacovigilance system to support our customers’ products and safeguard their patients.
References
- FDA – The Need for Artificial Intelligence in Pharmacovigilance
- EMA – Artificial Intelligence Publications and Updates
- CIOMS – Artificial Intelligence in Pharmacovigilance Report
- IQVIA – The Future of Pharmacovigilance: Integrating AI with Drug Safety Systems
- Applied Clinical Trials – How AI and Regulation Are Reshaping the Future of Drug Safety
- BioPharm International – Drug Safety, Artificial Intelligence, and Large Language Models
- PMC12317250
- PMC12335403
- TCS ADD – AI in Pharmacovigilance: Accelerating Innovation
- Baupharma – AI Automation in Drug Safety and Pharmacovigilance
- Binariks – Artificial Intelligence in Pharmacovigilance
- FDA – Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products
- FDA CDER – Emerging Drug Safety Technology Program
- EMA – Reflection Paper on the Use of Artificial Intelligence in the Medicinal Product Lifecycle